Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial)

CVIR Endovascular

Table 4 Hormone levels at baseline and 6 months

No	Group	Age	LH		FSH		E2
No	Group	Age	Baseline	6 months	Baseline	6 months	Baseline	6 months
1	E	34	2.90	2.60	4.10	5.50	287.00 ^c	83 ^c
2	E	43	33.40	28.30	31.90	36.70	< 70	< 70
3	E	45	2.60	4.20	3.70	4.10	614.00	411
4	E	48	2.70	3.30	5.70	6.90	315.00 ^c	< 70 ^c
5	E	40	16.80	12.40	39.50	29.80	< 70	< 70
6	E	51	< 0.5	23.00	< 0.5 ^b	24.80 ^b	104.00	228
7	E	41	7.10	21.40	15.00	18.60	135.00	408
8	E	46	5.50	6.80	8.10	2.70	136.00	724
9	E	42	0.90	1.20	3.80	3.40	119.00	224
10	E	32	7.80	11.90	5.10	6.60	316.00	259
11	G	45	3.80	4.50	3.60	6.10	307.00	336
12	G	45	5.30	4.00	4.70	1.70	405.00	837
13	G	36	5.80	4.10	10.20	3.70	183.00	119
14	G	43	3.80	7.20	5.70	7.00	110.00	648
15	G	52	11.30 ^a	26.00 ^a	17.10 ^b	57.90 ^b	243.00 ^c	< 70 ^c
16	G	52	32.20	53.10	31.30	78.00	420.00 ^c	< 70 ^c
17	G	41	< 0.5	0.90	< 0.5	1.90	< 70	< 70
18	G	46	0.90	8.40	4.00	9.60	310.00	252
19	G	47	1.80	5.40	2.30	6.90	< 70	140
20	G	52	9.50	11.30	35.90	41.40	< 70	< 70

^aRise in LH level to menopausal range at 6 months in 1 patient
^bRise in FSH level to menopausal range at 6 months in 1 patient
^cEstradiol levels dropped below normal range at 6 months in 4 patients
Normal range in pre-menopausal women for LH is 5 to 25 IU/L and FSH is 4.7–21.5 IU/L
Normal range for Estradiol (E2) in follicular phase is 77–920 pmol/L, mid cycle is 140–2380 pmol/L and luteal phase is 77–1145 pmol/L